Characterization of Large Structural Genetic Mosaicism in Human Autosomes  by Machiela, Mitchell J. et al.
REPORT
Characterization of Large Structural
Genetic Mosaicism in Human Autosomes
Mitchell J. Machiela,1 Weiyin Zhou,1,2 Joshua N. Sampson,1 Michael C. Dean,3 Kevin B. Jacobs,2,4
Amanda Black,1 Louise A. Brinton,1 I-Shou Chang,5 Chu Chen,6 Constance Chen,7 Kexin Chen,8
Linda S. Cook,9 Marta Crous Bou,7,10 Immaculata De Vivo,7,10 Jennifer Doherty,11
Christine M. Friedenreich,12 Mia M. Gaudet,13 Christopher A. Haiman,14 Susan E. Hankinson,10,15
Patricia Hartge,1 Brian E. Henderson,14 Yun-Chul Hong,16 H. Dean Hosgood, III,1,17 Chao A. Hsiung,18
Wei Hu,1 David J. Hunter,7,10,19 Lea Jessop,1 Hee Nam Kim,20 Yeul Hong Kim,21 Young Tae Kim,22
Robert Klein,23 Peter Kraft,7 Qing Lan,1 Dongxin Lin,24,25 Jianjun Liu,26,27 Loic Le Marchand,28
Xiaolin Liang,29 Jolanta Lissowska,30 Lingeng Lu,31 Anthony M. Magliocco,32 Keitaro Matsuo,33
Sara H. Olson,29 Irene Orlow,29 Jae Yong Park,34 Loreall Pooler,35 Jennifer Prescott,7,10 Radhai Rastogi,29
Harvey A. Risch,31 Fredrick Schumacher,14 Adeline Seow,36 Veronica Wendy Setiawan,14
Hongbing Shen,37,38 Xin Sheng,35 Min-Ho Shin,39 Xiao-Ou Shu,40 David VanDen Berg,14
Jiu-Cun Wang,41,42 Nicolas Wentzensen,1 Maria Pik Wong,43 Chen Wu,24,25 Tangchun Wu,44
Yi-Long Wu,45 Lucy Xia,35 Hannah P. Yang,1 Pan-Chyr Yang,46 Wei Zheng,47 Baosen Zhou,48
Christian C. Abnet,1 Demetrius Albanes,1 Melinda C. Aldrich,47,49 Christopher Amos,50
Laufey T. Amundadottir,1 Sonja I. Berndt,1 William J. Blot,47,51 Cathryn H. Bock,52 Paige M. Bracci,53
Laurie Burdett,1,2 Julie E. Buring,54 Mary A. Butler,55 Tania Carreo´n,55 Nilanjan Chatterjee,11Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA; 2Cancer Genomics Research Laboratory,
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Leidos Biomedical Research Inc., Bethesda, MD 20892, USA; 3Laboratory
of Experimental Immunology, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, MD 21702, USA; 4BioInformed LLC,
Gaithersburg, MD 20877, USA; 5National Institute of Cancer Research, National Health Research Institutes, Zhunan 35053, Taiwan, ROC; 6Division of
Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; 7Program in Genetic Epidemiology and Statistical Genetics,
Harvard School of Public Health, Boston, MA 02115, USA; 8Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute
and Hospital, Tianjin 300040, People’s Republic of China; 9University of New Mexico, Albuquerque, NM 87131, USA; 10Channing Division of Network
Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA; 11Geisel School of Medicine,
Dartmouth College, Lebanon, NH 03755, USA; 12Department of Population Health Research, CancerControl Alberta, Alberta Health Services, Calgary, AB
T2N 2T9, Canada; 13Epidemiology Research Program, American Cancer Society, Atlanta, GA 30303, USA; 14Department of Preventive Medicine, Keck
School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; 15Division of Biostatistics and Epidemiology, School of Public Health
and Health Sciences, University of Massachusetts Amherst, Amherst, MA 01003, USA; 16Department of Preventive Medicine, College of Medicine, Seoul
National University, Seoul 151-742, Republic of Korea; 17Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx,
NY 10461, USA; 18Institute of Population Health Sciences, National Health Research Institutes, Zhunan 35053, Taiwan, ROC; 19Broad Institute of
Harvard and MIT, Cambridge, MA 02142, USA; 20Center for Creative Biomedical Scientists, Chonnam National University, Gwangju 500-757, Republic
of Korea; 21Division of Oncology/Hematology, Department of Internal Medicine, College of Medicine, Korea University Anam Hospital, Seoul 151-742,
Republic of Korea; 22Department of Thoracic and Cardiovascular Surgery, Cancer Research Institute, College of Medicine, Seoul National University, Seoul
151-742, Republic of Korea; 23Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; 24Department
of Etiology & Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730,
People’s Republic of China; 25State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking
Union Medical College, Beijing 100730, People’s Republic of China; 26Department of Human Genetics, Genome Institute of Singapore, Singapore 138672,
Singapore; 27School of Life Sciences, Anhui Medical University, Hefei 230032, People’s Republic of China; 28Epidemiology Program, University of Hawaii
Cancer Center, Honolulu, HI 96813, USA; 29Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
USA; 30Department of Cancer Epidemiology and Prevention, Maria Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw 02-781, Poland;
31Yale School of Public Health, New Haven, CT 06510, USA; 32H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; 33Department of
Preventive Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka 819-0395, Japan; 34Lung Cancer Center, Kyungpook National University
Medical Center, Daegu 101, Republic of Korea; 35Department of Preventive Medicine, Keck School of Medicine, University of Southern California,
Los Angeles, CA 90007, USA; 36Saw Swee Hock School of Public Health, National University of Singapore, Singapore 119077, Singapore; 37Jiangsu Key
Laboratory of Cancer Biomarkers, Prevention, and Treatment, Nanjing Medical University, Nanjing 210029, People’s Republic of China; 38Ministry of
Education Key Laboratory of Modern Toxicology, Nanjing Medical University, Nanjing 210029, People’s Republic of China; 39Department of Preventive
Medicine, Chonnam National University Medical School, Gwanju 501-746, Republic of Korea; 40Department of Medicine, Vanderbilt Epidemiology
Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; 41Ministry of Education Key Laboratory of
Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai 200433, People’s Republic of China; 42State Key Laboratory of Genetic
Engineering, School of Life Sciences, Fudan University, Shanghai 200433, People’s Republic of China; 43Department of Pathology, Li Ka Shing Faculty of
Medicine, University of Hong Kong, Hong Kong SAR, People’s Republic of China; 44Institute of Occupational Medicine andMinistry of Education Key Lab-
oratory for Environment and Health, School of Public Health, Huazhong University of Science and Technology, Wuhan 430400, People’s Republic of
China; 45Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou 515200, People’s
Republic of China; 46Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei 10617, Taiwan, ROC; 47Division of Epide-
miology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; 48Department
of Epidemiology, School of Public Health, China Medical University, Shenyang 110001, People’s Republic of China; 49Department of Thoracic Surgery,
School of Medicine, Vanderbilt University, Nashville, TN 37232, USA; 50Department of Epidemiology, Division of Cancer Prevention and Population Sci-
ences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; 51International Epidemiology Institute, Rockville, MD 20850, USA;
The American Journal of Human Genetics 96, 487–497, March 5, 2015 487
Charles C. Chung,1,2 Michael B. Cook,1 Michael Cullen,1,2 Faith G. Davis,56 Ti Ding,57 Eric J. Duell,58
Caroline G. Epstein,1 Jin-Hu Fan,59 Jonine D. Figueroa,1 Joseph F. Fraumeni, Jr.,1 Neal D. Freedman,1
Charles S. Fuchs,10,60 Yu-Tang Gao,61 Susan M. Gapstur,13 Ana Patin˜o-Garcia,62
Montserrat Garcia-Closas,63 J. Michael Gaziano,64,65 Graham G. Giles,66 Elizabeth M. Gillanders,67
Edward L. Giovannucci,10,68 Lynn Goldin,1 Alisa M. Goldstein,1 Mark H. Greene,1 Goran Hallmans,69
Curtis C. Harris,70 Roger Henriksson,71 Elizabeth A. Holly,53 Robert N. Hoover,1 Nan Hu,1
Amy Hutchinson,1,2 Mazda Jenab,72 Christoffer Johansen,73,74 Kay-Tee Khaw,75 Woon-Puay Koh,36,76
Laurence N. Kolonel,28 Charles Kooperberg,6 Vittorio Krogh,77 Robert C. Kurtz,78 Andrea LaCroix,6
Annelie Landgren,1 Maria Teresa Landi,1 Donghui Li,79 Linda M. Liao,1 Nuria Malats,80
Katherine A. McGlynn,1 Lorna H. McNeill,81,82 Robert R. McWilliams,83 Beatrice S. Melin,71
Lisa Mirabello,1 Beata Peplonska,84 Ulrike Peters,6 Gloria M. Petersen,85 Ludmila Prokunina-Olsson,1
Mark Purdue,1 You-Lin Qiao,86 Kari G. Rabe,85 Preetha Rajaraman,1 Francisco X. Real,80,87 Elio Riboli,88
Benjamı´n Rodrı´guez-Santiago,87,89,90 Nathaniel Rothman,1 Avima M. Ruder,55 Sharon A. Savage,1
Ann G. Schwartz,52 Kendra L. Schwartz,91 Howard D. Sesso,54 Gianluca Severi,66,92 Debra T. Silverman,1
Margaret R. Spitz,93 Victoria L. Stevens,13 Rachael Stolzenberg-Solomon,1 Daniel Stram,14
Ze-Zhong Tang,57 Philip R. Taylor,1 Lauren R. Teras,13 Geoffrey S. Tobias,1 Kala Viswanathan,94
Sholom Wacholder,1 Zhaoming Wang,1,2 Stephanie J. Weinstein,1 William Wheeler,95 Emily White,6
John K. Wiencke,96 Brian M. Wolpin,10,60 Xifeng Wu,97 Jay S. Wunder,98 Kai Yu,1 Krista A. Zanetti,67
Anne Zeleniuch-Jacquotte,99,100 Regina G. Ziegler,1 Mariza de Andrade,85 Kathleen C. Barnes,101
Terri H. Beaty,94 Laura J. Bierut,102 Karl C. Desch,103 Kimberly F. Doheny,104 Bjarke Feenstra,105
David Ginsburg,106 John A. Heit,107 Jae H. Kang,10 Cecilia A. Laurie,108 Jun Z. Li,109
William L. Lowe,110 Mary L. Marazita,111,112 Mads Melbye,105,113 Daniel B. Mirel,19 Jeffrey C. Murray,11452Karmanos Cancer Institute and Department of Oncology, School of Medicine, Wayne State University, Detroit, MI 48201, USA; 53Department of Epide-
miology and Biostatistics, University of California, San Francisco, San Francisco, CA 94143, USA; 54Division of Preventive Medicine, Brigham andWomen’s
Hospital, Boston, MA 02115, USA; 55National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Cincinnati, OH
45226, USA; 56Department of Public Health Sciences, School of Public Health, University of Alberta, Edmonton, AB T6G 2R3, Canada; 57Shanxi Cancer
Hospital, Taiyuan, Shanxi 030013, People’s Republic of China; 58Unit of Nutrition, Environment, and Cancer, Cancer Epidemiology Research Program,
Catalan Institute of Oncology, Bellvitge Biomedical Research Institute,, Barcelona 08908, Spain; 59Shanghai Cancer Institute, Shanghai 200032, People’s
Republic of China; 60Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; 61Department of Epidemiology, Shanghai
Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotaong University Shanghai 200032, People’s Republic of China; 62Department of
Pediatrics, University Clinic of Navarra, Universidad de Navarra, Pamplona 31080, Spain; 63Division of Genetics and Epidemiology and Breakthrough
Breast Cancer Research Centre, Institute of Cancer Research, London, Surrey SM2 5NG, UK; 64Divisions of Preventive Medicine and Aging, Department
of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA; 65Massachusetts Veterans Epidemiology Research
and Information Center and Cooperative Studies Programs, Veterans Affairs Boston Healthcare System, Boston, MA 02130, USA; 66Cancer Epidemiology
Centre, Cancer Council Victoria and Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University
of Melbourne, Melbourne, VIC 3010, Australia; 67Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda,
MD 20892, USA; 68Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA; 69Nutritional Research Unit, Department of
Public Health and Clinical Medicine, Umea˚ University, Umea˚ 901 87, Sweden; 70Laboratory of Human Carcinogenesis, Center for Cancer Research,
National Cancer Institute, NIH, Bethesda, MD 20892, USA; 71Department of Oncology, Department of Radiation Sciences, Umea˚ University, Umea˚ 901
87, Sweden; 72International Agency for Research on Cancer, Lyon 69372, France; 73Department of Oncology, Finsen Centre, Rigshospitalet, Copenhagen
2100, Denmark; 74Unit of Survivorship Research, Danish Cancer Society Research Centre, Copenhagen 2100, Denmark; 75School of Clinical Medicine,
University of Cambridge, Cambridge CB2 1TN, UK; 76Duke-NUS Graduate Medical School, Singapore 169857, Singapore; 77Fondazione IRCCS Istituto
Nazionale dei Tumori, Milano 20133, Italy; 78Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; 79Department
of Gastrointestinal Medical Oncology, The University of Texas MDAnderson Cancer Center, Houston, TX 77030, USA; 80Spanish National Cancer Research
Centre, Madrid 28029, Spain; 81Department of Health Disparities Research, Division of OVP, Cancer Prevention and Population Sciences, The University of
Texas MD Anderson Cancer Center, Houston, TX 77030, USA; 82Center for Community-Engaged Translational Research, Duncan Family Institute,
The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; 83Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA;
84Nofer Institute of Occupational Medicine, Lodz 91-348, Poland; 85Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA;
86Department of Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences, Beijing 100730, People’s Republic of China; 87Departament de
Cie`ncies Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona 08003, Spain; 88Division of Epidemiology and Biostatistics, School of Public
Health, Imperial College London, London SW7 2AZ, UK; 89Centro de Investigacio´n Biome´dica en Red de Enfermedades Raras, Barcelona 08003, Spain;
90Quantitative Genomic Medicine Laboratory, qGenomics, Barcelona 08003, Spain; 91Karmanos Cancer Institute and Department of Family Medicine
and Public Health Sciences, School of Medicine, Wayne State University, Detroit, MI 48201, USA; 92Human Genetics Foundation, Torino 10126, Italy;
93Baylor College of Medicine, Houston, TX 77030, USA; 94Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University,
Baltimore, MD 21218, USA; 95Information Management Services Inc., Calverton, MD 20904, USA; 96University of California, San Francisco, San Francisco,
CA 94143, USA; 97Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; 98Division of Urologic
Surgery, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA; 99Department of Population Health, School of Medicine,
New York University, New York, NY 10016, USA; 100Perlmutter Cancer Institute, New York University, New York, NY 10016, USA; 101School of Medicine,
Johns Hopkins University, Baltimore, MD 21218, USA; 102Department of Psychiatry, School of Medicine, Washington University in St. Louis, St. Louis, MO
63110, USA; 103Department of Pediatrics and Communicable Diseases, C.S. Mott Children’s Hospital, University of Michigan, Ann Arbor, MI 48109, USA;
104Center for Inherited Disease Research, Institute of Genetic Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21218, USA;
105Department of Epidemiology Research, Statens Serum Institut, Copenhagen 2300, Denmark; 106Howard Hughes Medical Institute and Department
of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; 107Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905,
USA; 108Department of Biostatistics, University of Washington, Seattle, WA 98195, USA; 109Department of Human Genetics, University of Michigan,
Ann Arbor, MI 48109, USA; 110Division of Endocrinology, Metabolism, and Molecular Medicine, Feinberg School of Medicine, Northwestern University,
488 The American Journal of Human Genetics 96, 487–497, March 5, 2015
Sarah C. Nelson,108 Louis R. Pasquale,10,115 Kenneth Rice,108 Janey L. Wiggs,115 Anastasia Wise,116
Margaret Tucker,1 Luis A. Pe´rez-Jurado,87,89,117 Cathy C. Laurie,108 Neil E. Caporaso,1
Meredith Yeager,1,2 and Stephen J. Chanock1,*
Analyses of genome-wide association study (GWAS) data have revealed that detectable genetic mosaicism involving large (>2 Mb)
structural autosomal alterations occurs in a fraction of individuals. We present results for a set of 24,849 genotyped individuals
(total GWAS set II [TGSII]) in whom 341 large autosomal abnormalities were observed in 168 (0.68%) individuals. Merging data from
the new TGSII set with data from two prior reports (the Gene-Environment Association Studies and the total GWAS set I) generated a
large dataset of 127,179 individuals; we then conducted a meta-analysis to investigate the patterns of detectable autosomal mosaicism
(n ¼ 1,315 events in 925 [0.73%] individuals). Restricting to events >2 Mb in size, we observed an increase in event frequency as
event size decreased. The combined results underscore that the rate of detectable mosaicism increases with age (p value ¼ 5.5 3
1031) and is higher inmen (p value¼ 0.002) but lower in participants of African ancestry (p value¼ 0.003). In a subset of 47 individuals
from whom serial samples were collected up to 6 years apart, complex changes were noted over time and showed an overall increase
in the proportion of mosaic cells as age increased. Our large combined sample allowed for a unique ability to characterize detectable
genetic mosaicism involving large structural events and strengthens the emerging evidence of non-random erosion of the genome in
the aging population.Detectable mosaicism is the presence of two or more genet-
ically distinct populations of cells in an individual who has
developed from a single zygote.1 The clonal expansion of
acquired post-zygotic mutations, such as large-scale gains,
losses, and copy-neutral uniparental disomy, can result
in the co-existence of aberrant cellular populations with
normal germline DNA.2 Clonal mosaicism can also con-
tribute to diverse phenotypes depending on developmental
timing, the tissue involved, the genomic location of the
mutation, and the percentage of cellular populations
affected.3–5 Compared to constitutional defects in the
same regions, mosaic abnormalities can result in milder
phenotypes, as observed for neurofibromatosis type 1
(MIM162200) and trisomy 21 (MIM190685); interestingly,
these same mutations have been observed in apparently
healthy individuals.6–8 A spectrum of clinical phenotypes,
including Maffucci syndrome (MIM 614569),9,10 McCune-
Albright syndrome (MIM 174800),11 nevus sebaceus (MIM
162900),12 Ollier disease (MIM 166000),9,10 Proteus syn-
drome (MIM 176920),13 and mosaic RASopathies,14 have
been associated with mosaicism.
Until recently, estimates of the rates of humanmosaicism
involving large structural events were unavailable.15 Early
evidence demonstrated somaticmosaicism inmonozygotic
twins16 and differentiated human tissues17 but provided no
estimates of rates in human populations. The combination
of large datasets and improvedmethodology for analysis of
genome-wide SNP microarray data has enabled genome-
wide surveys of large structural mosaic events in blood
and buccal DNA.18,19 An initial population-based case-
control genome-wide association study (GWAS) of 1,991 in-
dividuals with bladder cancer reported autosomal mosaic
abnormalities (e.g., structural events >2 Mb) in blood orChicago, IL 60208, USA; 111Center for Craniofacial and Dental Genetics, Depa
Pittsburgh, PA 15260, USA; 112Department of Human Genetics, Graduate Sch
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The AmebuccalDNA from1.7%of the overall study sample.18 Subse-
quent analyses of a larger set of GWASs involving 57,853
individuals, described as the total GWAS set I (TGSI),
presented evidence that clonal mosaicism was strongly
associated with greater age and weakly associated with
male gender and overall solid-tumor risk, in particular
lung and kidney cancer.20 A concurrently published study,
involving 50,222 individuals, from the Gene-Environment
Association Studies (GENEVA) Consortium observed an
association between mosaicism and age, although no sig-
nificant associations were observed with gender or solid
tumors.21 An additional study by Forsberg and colleagues
detected age-related structural changes in leukocyte DNA
from paired monozygotic twins and single-born subjects
in 3.4% of individuals aged 60 years or older but failed to
detect mosaic events in individuals aged 55 years or
younger.22 Other studies have subsequently confirmed
the presence of detectable autosomal mosaicism in older
populations,23,24 as well as demonstrated an age-specific
relationship with mosaicism on the Y chromosome.25
Furthermore, recent evidence indicates that somatic mosa-
icism might be an important contributor to unexpected
familial recurrences of genomic disorders.26
We confirmed the presence of clonal mosaic events
greater than 2 Mb in an independent sample set of can-
cer-affected individuals and control individuals and con-
ducted a meta-analysis of the events from our sample set
and the two prior investigations to refine our understand-
ing of the landscape of events. Study subjects from our new
sample set, hereafter referred to as the total GWAS set II
(TGSII), were drawn from published GWASs investigating
cancer-susceptibility risk and were analyzed in the Cancer
Genomics Research Laboratory of the National Cancerrtment of Oral Biology School of Dental Medicine, University of Pittsburgh,
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Institute. TGSII includes 24,849 participants drawn from
46 studies on populations of European, Asian, and African
descent. Approval by the institutional review board for
each study was confirmed, and written informed consent
was obtained.
TGSII genotyping was carried out on commercially avail-
able Illumina Infinium BeadArray human assays (Human-
Hap610, HumanHap660W, HumanHap1M, OmniExpress,
Omni1, Omni2.5, and Omni5). Assays, specimens, and
participants met the following criteria for inclusion: (1) in-
formation was available on the first cancer site, or individ-
uals were determined to be cancer free, (2) the minimum
genotype completion rate was 88%, (3) SDs were less
than 0.33 and 0.05 for the final corrected log2 R ratio
(LRR) and B allele frequency (BAF), respectively, and (4) ge-
netic identity was consistent across duplicate samples.
To assess copy-number changes and allelic imbalances,
we estimated LRR and BAF. LRR provides a metric for as-
sessing copy-number change via the calculation of log2
of the ratio of observed total signal intensities to expected
signal intensities for a SNP. LRR values greater than 0 indi-
cate mosaic copy gain, whereas values less than 0 indicate
loss. The BAF, a measure of allelic imbalance, is calculated
as the ratio of signal intensity between two alleles at each
SNP in relation to estimated genotype clusters; it is thus
a calculation of the frequency of the B allele for a biallelic
SNP with alleles A and B. BAF values for heterozygous SNPs
that deviate from 0.5 are indicative of mosaic copy-num-
ber changes or copy-neutral changes associated with ac-
quired uniparental disomy.
To improve accuracy, we used a quantile normalization
approach similar to that used by Staaf et al.27 and Diskin
et al.28 because LRR and BAF estimates from Illumina Ge-
nomeStudio software suffer biases from assay chemistry
and DNA concentration. For TGSI and TGSII, a mosaic-
alteration-detection algorithm incorporated into the
software package R-GADA (based on genome alteration
detection analysis) was used to detect clonal mosaic events
greater than 2 Mb in size from corrected LRR and BAF
values.19,29 The GADA segmentation algorithm detected
clonal mosaic regions by identifying breakpoints in Bdev
values with the use of sparse Bayesian learning and back-
ward elimination. The assigned event type was based on
the mean LRR value, and the mosaic proportion of
abnormal cells was estimated from the BAF values. The
detection algorithm has been previously validated with
laboratory techniques (e.g., single tandem repeat, multi-
plex ligation-dependent probe amplification, and fluores-
cent in situ hybridization)18 and is described in greater
detail in the methods and supplementary material of the
original Jacobs et al. analysis.20 Investigators blind to study
outcomes conducted a manual review to confirm events in
TGSI and TGSII. Common modifications included adjust-
ing boundaries of mosaic events or merging or separating
adjacent events.
To improve our understanding of the landscape of clonal
mosaic events, we first combined TGSI20 and TGSII, both490 The American Journal of Human Genetics 96, 487–497, March 5of which were analyzed with the identical pipeline
described above. Subsequently, we extracted events >2
Mb from the Laurie et al. study (GENEVA).21 GENEVA
used a circular-binary-segmentation algorithm with the
Bioconductor packages DNACopy and GWASTools. The
overall reproducibility between the GENEVA algorithm
and TGSI algorithm in detecting events >2 Mb was as-
sessed in 5,510 lung cancer samples included in both
GENEVA and TGSI. The comparability in called events
>2 Mb was 75%; 83 of the total 111 events were detected
by both algorithms, 20 were detected by TGSI only, and
8 were detected by GENEVA only. The 5,510 replicated
lung cancer samples and 235 individuals with inadequate
consent were removed from the GENEVA sample in the an-
alyses described herein. For more details on the detection
methods, please see the methods and supplementary ma-
terials in the previously published TGSI20 and GENEVA21
reports, which include laboratory confirmation of select
samples in TGSI.
In the 24,849 individuals in TGSII, our method detected
341 clonal mosaic events across 255 autosomes in 168 in-
dividuals (Table S1). We detected 69 events (20%) with
mosaic copy gain, 90 events (26%) with mosaic copy
loss, and 163 events (48%) with copy-neutral acquired uni-
parental disomy. 19 events (6%) were complex in nature
and not amenable to distinct classification.
Detected events from our TGSII were combined with
TGSI, and then a meta-analysis with GENEVA was per-
formed on a sample set of a total of 127,179 individuals,
in whom 1,315 mosaic events were detected in 925 partic-
ipants; the overall rate of individuals with detected mosai-
cism was 0.73% (95% confidence interval [CI] ¼ 0.68–
0.78%). Of the 925 participants with detected events,
797 (86%) had only one event, and 128 (14%) harbored
multiple mosaic events. Compared to the Poisson expecta-
tion, which is that only seven individuals have multiple
events, a highly significant excess of individuals with mul-
tiple events was observed (p value ¼ 6.5 3 1030).
Although complex rearrangements affecting multiple re-
gions of the genome could partially account for the excess,
differences inmosaic proportion of events in some individ-
uals suggest more complex mechanisms over long periods
of time as well.
Approximately half of the detected events were mosaic
copy-neutral uniparental disomy (48%), followed by
mosaic losses (34%) and mosaic gains (17%). To charac-
terize genomic location and potential recurring events,
we generated Circos plots.30 The majority of mosaic gains
were observed on chromosomes 8, 12, and 15, themajority
of mosaic losses were observed on chromosomes 13 and
20, and mosaic copy-neutral events were primarily
observed on chromosomes 9 and 14 (Figure 1). Detected
mosaic events clustered regionally on chromosomal arms
on the basis of their copy-number state (Table 1). Mosaic
copy-neutral events occurred primarily on the telomeric
ends of chromosomes; 33% included the p telomere, and
54% included the q telomere. Mosaic losses were, 2015
Figure 1. Genomic Locations of the Combined 1,334 Events Overall and by Cancer Status
Green indicates mosaic copy gains, blue represents mosaic copy-neutral events, and red represents mosaic losses.
(A) All 1,334 events from the combined GENEVA, TGSI, and TGSII analysis.
(B) Events in cancer-free control individuals.
(C) Events in individuals with solid tumors.commonly observed in interstitial chromosomal regions
that did not involve telomeres or centromeres. Of all of
the copy-number states, mosaic gains most commonly
involved whole chromosomes. Only 1.7% of events were
interstitial and spanned the centromere, suggesting that
for interstitial mosaic events, involvement of a centromere
could be uncommon.
It is notable that losses at certain regions, such as 20q
(chr20: 40,425,000–42,155,000; UCSC Human Genome
Browser hg18) and 13q14 (chr13: 49,590,000–49,983,100;
UCSC hg18), are observed in leukemias (e.g., myelogenous
and lymphoblastic leukemia, respectively).31–33 Clustering
of losses in these regions suggests that these events are
non-random. Moreover, aggregation of mosaic-event
locations on chromosomal arms by copy-number state
suggests common mechanisms. For example, copy-neutral
telomeric events could be due to mitotic recombination
followed by clonal expansion. Breakpoint analyses of
regions surrounding mosaic events might aid in under-
standing mechanisms responsible for event initiation,
but the current resolution of event boundaries in SNP
microarrays is limited as a result of insufficient probe
density. Further work is required to investigate the
different types of events that could lead to large structural
mosaicism.Table 1. Distribution of Mosaic Copy-Number State by Chromosomal
Gain Neutral
Whole chromosome 60 (65%, 27%) 25 (27%, 4
Telomeric p 18 (7%, 8%) 205 (78%, 3
Telomeric q 67 (15%, 30%) 338 (75%, 5
Interstitial 73 (16%, 33%) 51 (11%, 8
Spans centromere 5 (22%, 2%) 10 (43%, 2
Total 223 (17%, 100%) 629 (49%, 1
Events classified as ‘‘whole chromosome’’ from the combined dataset span an en
telomere on the p or q arm, respectively, ‘‘interstitial’’ events do not include a telo
overlap a chromosome’s centromere. Event counts are indicated in parentheses (
The AmeTo identify characteristics associated with increased risk
of large clonal mosaic events, we evaluated age, gender,
ancestry, and cancer status. Age at time of DNA collection
was available for all GENEVA and TGSI participants, but for
TGSII participants, the date of diagnosis (for cancer sub-
jects) or the age at the time of participation (for control
subjects) was substituted when age at time of DNA collec-
tion was missing. Categorical variables were constructed
for the 5-year age groups of 50–54, 55–59, 60–64, 65–69,
and 70–74 and for 75 years or older, whereas individuals
under 50 years of age were considered the reference group.
We used reference populations from the HapMap project34
and the GLU (Genotype Library and Utilities) software
package to estimate continental-ancestry proportions for
each individual. Terms were fit for percentage of African
and Asian ancestry, whereas European ancestry served as
the referent. Indicator variables were used for adjusting an-
alyses for effects related to the individual contributing
studies. Sensitivity analyses using mixed models, case-con-
trol matching, and pooled analyses were also used to inves-
tigate the robustness of statistically significant findings. All
statistical analyses were performed in R version 3.0.1 on a
64-bit Unix platform.35
Increasing age is the variable most strongly associated
with clonal mosaicism (Figure 2). In logistic regression-Arm Location
Loss Total
%) 8 (9%, 2%) 93 (100%, 7%)
3%) 40 (15%, 9%) 263 (100%, 20%)
4%) 44 (10%, 10%) 449 (100%, 35%)
%) 344 (74%, 77%) 468 (100%, 36%)
%) 8 (35%, 2%) 23 (100%, 2%)
00%) 444 (34%, 100%) 1,296 (100%, 100%)
tire chromosome, ‘‘telomeric p’’ and ‘‘telomeric q’’ are events that include the
mere or centromere, and ‘‘spans centromere’’ indicates interstitial events that
row percent, column percent).
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Figure 2. Proportion of Mosaic Individuals across 5-Year Age
Groups in the Combined GENEVA, TGSI, and TGSII Dataset by
Cancer Status
Affected individuals are in red, and cancer-free control individuals
are in blue. Error bars represent 95% CIs. An overall significant
relationship in the proportion of individuals with mosaic events
was observed with age (p value ¼ 1.131030).
Figure 3. Forest Plots of Associations with Clonal Mosaicism
Associations between clonal mosaicism and (A) age-group, (B)
gender, and (C) ancestry.models adjusted for gender, ancestry, cancer subtype, and
contributing study, highly significant age effects were
observed in both a meta-analysis and a pooled analysis of
GENEVA, TGSI, and TGSII (Figure 3A). The effect of the
5-year age groups was significantly associated with detect-
able clonal mosaicism overall (p value ¼ 5.5 3 1031),
showed no evidence of heterogeneity across the study
(p value ¼ 0.71), and remained significant when the anal-
ysis was restricted to a subset of cancer-free control indi-
viduals (p value ¼ 8.92 3 1012). Compared to individuals
under 50 years old, individuals aged 75 years or older
had an approximate 6-fold increase in detection of large-
scale mosaic events (p value ¼ 2.22 3 1016, 95% CI ¼
4.16–10.09).
Ourmeta-analysis strengthens the robust age association
previously observed in GENEVA and TGSI. Although the
inclusion of age at diagnosis as a substitute for age at the
time of DNA collection could have introduced measure-
ment error in individual TGSII participants, the TGSII
and overall pooled age association agree with the original
age estimates from the GENEVA and TGSI studies.
Although an association with age was observed, it is impor-
tant to note that our analysis does not provide insight into
whether the events were generated early in life and later
positively selected by rapid expansion of a second clonal
population or generated later in life as a result of decreased
cellular diversity and senescence.
The effect of gender was also significant. Mosaic events
were more frequently observed in males than in females
(0.98% versus 0.56%, respectively; Figure 3B). Removing492 The American Journal of Human Genetics 96, 487–497, March 5sex-specific cancers (e.g., endometrial and prostate can-
cers) and adjusting for ancestry, 5-year age group, cancer
subtype, and contributing study, we found a significant
association with male gender (odds ratio [OR] ¼ 1.44,
95% CI ¼ 1.15–1.81, p value ¼ 0.002) and no evidence
of heterogeneity of effect across the study (p value ¼
0.88). In the 37,942 cancer-free control individuals, the, 2015
Table 2. Solid-Tumor Associations with Clonal Mosaicism
n OR 95% CI p Value
Overall 46,831 1.29 1.11–1.50 0.0008
Bladder 4,995 1.29 0.90–1.85 0.168
Breast 2,814 1.06 0.53–2.10 0.869
Endometrium 872 2.66 1.16–6.12 0.021
Esophagus 1,910 0.89 0.34–2.34 0.821
Glioma 1,729 0.78 0.30–2.06 0.622
Kidney 1,565 1.81 1.06–3.11 0.031
Liver 13 10.40 1.32–81.9 0.026
Lung 13,015 1.54 1.21–1.97 0.001
Ovary 543 2.60 0.93–7.28 0.069
Pancreas 3,923 0.83 0.53–1.29 0.404
Prostate 10,456 1.27 1.00–1.60 0.046
Skin 1,949 0.96 0.43–2.13 0.911
Stomach 2,278 1.52 0.70–3.28 0.292
Testis 649 1.77 0.24–13.0 0.573
Combined analysis of solid-tumor associations adjusted for gender, ancestry, 5-year age group, and contributing study. ‘‘n’’ denotes total sample size. ORs and
95% CIs are reported for solid tumors overall and by cancer subtype.gender association was of similar magnitude but margin-
ally not significant (OR¼ 1.39, p value¼ 0.06), most likely
as a result of the reduced number of individuals with
events (n ¼ 303). The elevated rates of mosaic events
observed in males could be partially attributable to higher
male-specific rates of hematologic malignancies, a set of
malignancies previously found to be associated with clonal
mosaicism.20,21,23 Further work will be required for under-
standing the scope and implications of this observation.
An association between genotype-inferred ancestry
(defined as the percentage of continental origin from
Africa, Asia, or Europe) and clonal mosaic events was also
evident (Figure 3C). Logistic regression analyses adjusted
for gender, 5-year age group, cancer subtype, and study
indicated that relative to individuals of European ancestry,
individuals of African ancestry were at a reduced risk (OR¼
0.38, 95% CI ¼ 0.21–0.71, p value ¼ 0.003). Heterogeneity
testing detected no heterogeneity (p value ¼ 0.66), and the
effect retained significance when the analysis was
restricted to cancer-free control individuals (OR ¼ 0.23,
95%CI¼ 0.09–0.60, p value¼ 0.003). No significant differ-
ence was observed between Asian and European ancestry.
Mechanisms relating to ancestry-specific differences in
rates of clonal mosaicism are poorly understood, and
further work is needed for better understanding this
relationship.
We further investigated the associations between clonal
mosaicism and risk of solid (non-hematological) tumors
overall and of tumor subtypes as per the previous TGSI
finding.20 Analyses adjusted for gender, ancestry, 5-year
age group, and contributing study indicated thatThe Amesolid tumors were associated with clonal mosaicism in
blood or buccal tissue (OR ¼ 1.29, 95% CI ¼ 1.11–1.50,
p value ¼ 8.1 3 104). Additional cancer-specific analyses
were performed for all solid-tumor subtypes present in
our study (Table 2). Endometrial, kidney, liver, lung, and
prostate cancers suggested preliminary evidence of sig-
nificant associations with clonal mosaicism; however,
only lung cancer maintained statistical significance after
correction for multiple testing. Interestingly, all solid-
tumor subtypes showing preliminary evidence of an asso-
ciation with mosaicism had ORs greater than 1, but the
sample sizes per tumor were small, and the estimates
were unstable for the risk effects measured. Circos plots
showing mosaic-event location for cancer-free control
individuals and for individuals with solid tumors are
displayed in Figures 1B and 1C. No differences in event
clustering or copy-number state were observed among
the individuals with solid tumors. Lung cancer was the
primary contributor to the overall cancer association,
and it is notable that lung cancer is a smoking-related
cancer; however, previous data suggest that smoking is
not significantly associated with autosomal mosaicism
in blood tissue.20,21 Potential mechanisms linking clonal
mosaicism in blood to solid-tumor risk might include
poor overall genome maintenance unable to repair
genomic alterations or immunologic dysfunction in
mosaic immune cells and the subsequent poor clearance
of pre-cancerous cells from solid tissues. Further studies
are required to determine whether detectable clonal mosa-
icism could be a useful biomarker in screening individuals
for increased risk of developing solid tumors. This is inrican Journal of Human Genetics 96, 487–497, March 5, 2015 493
Figure 4. Relationship betweenMosaic Event Size and Detected
Rate
Counts of detected mosaic events from the combined analysis are
plotted in 10-Mb bin sizes. An inverse exponential trend, repre-
sented by the dotted line, was fit to the counts (R2 ¼ 0.81). Fitted
coefficients (b) and 95% CIs are displayed in the plot.contrast to hematological malignancies, in which detect-
able mosaicism in blood could be an early indicator of
leukemic and pre-leukemic clones.20,21,23
An association between rate and event size was noted:
smaller events were observed to have higher rates
than larger events (Figure 4). An inverse exponential rela-
tionship fit the trend well (R2 ¼ 0.81). This association
was also present in the substrata of mosaic gains, copy-
neutral events, and losses. This suggests that smaller auto-
somal events are more frequent and that larger autosomal
events are relatively more rare. Event size was also investi-
gated across copy-number states (Figure 5A). With a me-
dian event size of 60.8 Mb, mosaic copy gains, on average,
were largest. Mosaic copy-neutral events and mosaic losses494 The American Journal of Human Genetics 96, 487–497, March 5had median sizes of 39.8 and 17.0 Mb, respectively. The
larger average size of mosaic gains and copy-neutral events
might highlight the detrimental nature of induced mono-
somy and reduced copy number of mosaic losses and pro-
vide insight into understanding which mutational events
undergo clonal selection. By restricting our analysis to
events larger than 2 Mb in size to reduce the false-positive
rate of our detection algorithm, we most likely missed
many smaller mosaic events, frommosaic point mutations
to events several kilobases in size. Extrapolating our obser-
vations to smaller events suggests that the copy-number
distribution of these events is most likely skewed toward
mosaic losses. This could prove to have great importance
in both disease risk and heterogeneity of disease pheno-
types. Although the association between event rate and
size was present in every strata of copy-number state, the
overall association might be skewed by the abundance of
small copy losses in likely driver regions of hematologic
cancers, such as losses at 13q14 and 20q. Further refine-
ments in genotyping technologies and detection algo-
rithms targeted at detecting smaller mosaic events in
next-generation sequencing should refine our understand-
ing of the landscape of detectable clonal mosaicism.
Mosaic proportion, namely, the percentage of cells with
large structural events that differ from germline DNA, was
distinct across event copy-number state (Figure 5B).Mosaic
copy gains and copy losses were observed, on average, to
have higher mosaic proportions (medians of 0.35 and
0.33, respectively), whereas mosaic copy-neutral events
had a lower median proportion of 0.19. The range of the
mosaic proportions provides insight into the detectable
range of our methodology. Copy-neutral mosaic events
can be detected in the range 0.06–0.95, whereas mosaic
copy gains can be detected in the range 0.10–0.90.
The relationship between age and mosaic proportion
was also investigated (Figure 6). A significant positive as-
sociation between age and mosaic proportion was
observed for copy-neutral events (p value ¼ 1.2 3 104),
suggesting that on a population level, mosaic proportionFigure 5. Event Size and Mosaic-Propor-
tion Distribution across Copy-Number
State
Violin plots of combined sample event size
(A) and mosaic proportion (B) in relation-
ship to mosaic copy gains, copy-neutral
uniparental disomies, and copy losses.
Boxplots with white circles denoting the
median and thick black boxes representing
the interquartile range are encapsulated
in kernel density plots of the distribution
of event length. Numbers below and above
the violin plots of mosaic proportion
(B) indicate the minimum and maximum
detected range observed for each respec-
tive event’s copy-number state.
, 2015
Figure 6. Characterization of Changes in
Mosaic Proportion with Age
Mosaic proportion is stratified across event
copy-number state (columns) and age cate-
gory (x axis) from the combined analysis.
Points represent estimates of the mean,
and error bars indicate 95% CI around
the mean. Best-fit regression lines are
plotted with dotted lines, and p values
are shown for slopes that are significantly
different from 0.might gradually increase with age. To further assess the
evolution of mosaic events over time, we analyzed serial
samples from the Prostate, Lung, Colon, and Ovary Pre-
vention Trial (PLCO). Two to four DNA samples collected
at least 1 year apart were analyzed for PLCO individuals
with detectable clonal mosaicism in TGSI and TGSII. In
total, we tracked large structural mosaic events for 58 au-
tosomes (Figure 7) detected in 47 individuals. The set
included 24 events with mosaic loss, 27 with copy-neutral
loss of heterozygosity, and 7 with gain. Although exam-
ples existed where events had stable or decreasing mosaic
proportion over time, most events were observed to in-
crease in mosaic proportion. Fitting a linear mixed model
with a zero intercept and a random effect for each event,
our analysis suggests that with each year increase in age,
the overall fraction of mosaic proportion increases on
average by approximately 1.44% (p value ¼ 3.3 3 107).
Significant increases in mean mosaic proportion were
seen over time in the strata of mosaic losses and mosaic
copy-neutral events, but because of limited sample size
(n ¼ 7), the increase was not significant for mosaic gains.
Together, these observations suggest that most detectableFigure 7. Changes in Percentage of Mosaicism of Serial Samples o
(A) Lines (red for copy loss, blue for copy neutral, and green for co
males, and circles represent females) for each mosaic chromosome
increasing age.
(B) Events are plotted with zero origin and a mixed model for a su
estimated average change in mosaic proportion per year (1.44%, p v
The Amemosaic events confer some form of selective advantage
that enables cellular clones to increase in frequency over
time in relation to cells with normal karyotypes.
A few limitations relating to the available data are worth
considering. The studies used for analysis were primarily
designed as GWASs of cancer (GENEVA, TGSI, and TGSII)
and other traits (GENEVA), and study participants were
drawn from cohort and case-control studies. Rate estimates
of mosaicism, as provided by the combination of individ-
uals included in these studies, could imperfectly represent
underlying population prevalence. However, the con-
sistency of effect estimates across GENEVA, TGSI, and
TGSII suggests that our findings are robust. Additionally,
although incomplete, adjustment for factors such as age
group, gender, ancestry, cancer subtype, and contributing
study minimized confounding effects. Because additional
bioinformatics methods are needed to detect mosaicism
on the sex chromosomes and because there is poor com-
mercial array coverage of the Y chromosome, this report
focused on detectable autosomal mosaicism. Another
group has reported a similar association between Y mosai-
cism and increasing age.25ver Time
py gain) connect DNA-collection time points (triangles represent
(n ¼ 58) to track changes in the percentage of mosaicism with
bject with zero random-effect fit (solid black line), showing the
alue ¼ 3.3 3 107).
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Our analysis is distinctive in that it involves a meta-
analysis of 127,179 individuals and thus provides a more
comprehensive portrait of the landscape of large structural
mosaic genetic alterations. Our meta-analysis allowed for a
more precise age effect, strengthened prior evidence of a
gender effect, and found evidence of an ancestry effect.
Additionally, we found evidence indicating that the
number of mosaic events increases as event size decreases,
suggesting that our detected events might represent the
tip of the iceberg in relation to many smaller mosaic
events that most likely exist and are currently undetected.
Furthermore, we were able to analyze serial samples over
multiple collection time points to show an overall increase
in mosaic percentage as age increases.
The investigation of human clonal mosaicism can
provide new insights into aging, as well as shed light on
possible precursors of disease. Our results suggest that
genome maintenance, particularly in relation to aging,
could have pleotropic consequences, although it is not
clear whether all mosaic events are necessarily deleterious.
The long-held assumption that germline DNA remains
static during the course of life is under reconsideration,
which is particularly important for the comparative study
of cancer genomes. As the detection of smaller mosaic
events across tissue types improves, we can refine our
understanding of the landscape of mosaic events across
the spectrum of genetic events. In turn, this could repre-
sent an important step toward the investigation of how
our once ‘‘stable’’ germline DNA might slowly erode into
a complex mosaic over time and contribute to disease
heterogeneity.Supplemental Data
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